Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 5 min ago
Peer-reviewedLicence not statedNew England Journal of Medicine

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

  • Caicun Zhou1,2
  • Laurent Greillier3
  • Geoffrey Liu4
  • Thomas John5
  • Ligang Xing6
  • Dariusz Mirosław Kowalski7
  • Regan Michelle Memmott8
  • Ozan Yazici9
  • Meili Sun10
  • Catherine Shu11
  • Elvire Pons Tostivint12
  • Yun Fan13
18 more authors
  • G. Fernández-Hinojal14
  • Elaine Shum15
  • Mengzhao Wang16
  • Federica Bertolini17
  • David Ross Camidge18
  • Chengzhi Zhou1,2
  • Ludovic Doucet19
  • 洪群英20
  • Jian Fang21
  • Dingzhi Huang22
  • Bo Jin23
  • Yan Yu24
  • Lorenzo Antonuzzo25
  • Denis Moro‐Sibilot26
  • Jaafar Bennouna27
  • Gilberto de Castro28
  • Li Zheng29
  • John Victor Heymach30
30 affiliations
  1. 1First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  2. 2Shanghai East Hospital, Shanghai
  3. 3Assistance Publique–Hôpitaux de Marseille, Hôpital Nord, Marseille, France
  4. 4Princess Margaret Cancer Centre, University Health Network, Toronto
  5. 5Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  6. 6Shandong Cancer Hospital, Jinan, China
  7. 7Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Klinika Nowotworow Pluca i Klatki Piersiowej, Warsaw, Poland
  8. 8Ohio State University Brain and Spine Hospital, Columbus
  9. 9Gazi University Faculty of Medicine Hospital, Ankara, Turkey
  10. 10Central Hospital Affiliated to Shandong First Medical University, Jinan, China
  11. 11Columbia University Medical Center, New York
  12. 12Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France
  13. 13Zhejiang Cancer Hospital, Hangzhou, China
  14. 14Clinica Universidad de Navarra, Madrid
  15. 15Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
  16. 16Peking Union Medical College Hospital, Beijing
  17. 17Oncology, Modena University Hospital, Modena, Italy
  18. 18University of Colorado Hospital–Anschutz Cancer Pavilion (ACP), Aurora
  19. 19Institut de Cancérologie de L’Ouest, Nantes, France
  20. 20ZhongShan Hospital, Fudan University, Shanghai
  21. 21Beijing Cancer Hospital, Beijing
  22. 22Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  23. 23First Hospital of China Medical University, Shenyang
  24. 24Harbin Medical University Cancer Hospital, Harbin, China
  25. 25Azienda Ospedaliero Universitaria Careggi, Florence, Italy
  26. 26CHU Grenoble Alpes, Hôpital Albert Michallon, La Tronche, France
  27. 27Hôpital Foch, Suresnes, France
  28. 28Instituto do Cancer do Estado de São Paulo, São Paulo
  29. 29Dizal Pharmaceutical, Shanghai
  30. 30University of Texas M.D. Anderson Cancer Center, Houston
Open at sourcePDFDOICite

Related

  1. High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
    Yoshihiko Sakata, Kenta Murotani, Daichi Fujimoto +18
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
    Jinyong Kim, Sehhoon Park, Gyeong-Won Lee +16
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  3. Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries
    Ana Caroline Zimmer Gelatti, Eldsamira Mascarenhas, Guilherme Harada +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  4. Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study.
    Dong Yan, Chaoying Liu, Xingya Li +10
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.
    Yingding Ruan, Hongsheng Xue, Chuan Long +3
    BMC cancerPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{zhou2026firstline,
  title = {{First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations}},
  author = {Caicun Zhou and Laurent Greillier and Geoffrey Liu and Thomas John and Ligang Xing and Dariusz Mirosław Kowalski and Regan Michelle Memmott and Ozan Yazici and Meili Sun and Catherine Shu and Elvire Pons Tostivint and Yun Fan and G. Fernández-Hinojal and Elaine Shum and Mengzhao Wang and Federica Bertolini and David Ross Camidge and Chengzhi Zhou and Ludovic Doucet and 洪群英 and Jian Fang and Dingzhi Huang and Bo Jin and Yan Yu and Lorenzo Antonuzzo and Denis Moro‐Sibilot and Jaafar Bennouna and Gilberto de Castro and Li Zheng and John Victor Heymach},
  journal = {New England Journal of Medicine},
  year = {2026},
  month = may,
  doi = {10.1056/nejmoa2604461},
  url = {https://hdl.handle.net/2158/1499878},
}
RIS
TY  - JOUR
TI  - First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
AU  - Caicun Zhou
AU  - Laurent Greillier
AU  - Geoffrey Liu
AU  - Thomas John
AU  - Ligang Xing
AU  - Dariusz Mirosław Kowalski
AU  - Regan Michelle Memmott
AU  - Ozan Yazici
AU  - Meili Sun
AU  - Catherine Shu
AU  - Elvire Pons Tostivint
AU  - Yun Fan
AU  - G. Fernández-Hinojal
AU  - Elaine Shum
AU  - Mengzhao Wang
AU  - Federica Bertolini
AU  - David Ross Camidge
AU  - Chengzhi Zhou
AU  - Ludovic Doucet
AU  - 洪群英
AU  - Jian Fang
AU  - Dingzhi Huang
AU  - Bo Jin
AU  - Yan Yu
AU  - Lorenzo Antonuzzo
AU  - Denis Moro‐Sibilot
AU  - Jaafar Bennouna
AU  - Gilberto de Castro
AU  - Li Zheng
AU  - John Victor Heymach
PY  - 2026
DA  - 2026/05/29
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2604461
UR  - https://hdl.handle.net/2158/1499878
SN  - 0028-4793
SN  - 0096-6762
SN  - 1533-4406
SN  - 2331-4710
ER  -